Ankarao A. et al. / International Journal of Biopharmaceutics. 2013; 4(1): International Journal of Biopharmaceutics

Similar documents
Scholars Research Library. Formulation and evaluation of buccoadhesive tablet of Atenolol

Formulation and Development of Sustained Release Tablets of Valsartan Sodium

FABRICATION AND EVALUATION OF GLIMEPIRIDE CORDIA DICHOTOMA G.FORST FRUIT MUCILAGE SUSTAINED RELEASE MATRIX TABLETS

Bioadhesive Polymer Buccal Tablets for Losartan Potassium Controlled Delivery: Formulation, In-vitro and Ex-vivo Evaluation

A Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac

International Journal of Medicine and Pharmaceutical Research

Available Online through Research Article

STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS

Important Characterization of Nicorandil Buccal Tablets

Volume: 2: Issue-3: July-Sept ISSN FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF NICORANDIL

DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN

Asian Journal of Research in Biological and Pharmaceutical Sciences

Bahadur S. et al /J. Pharm. Sci. & Res. Vol.1(4), 2009,

FORMULATION AND EVALUATION OF VALSARTAN TABLETS EMPLOYING CYCLODEXTRIN-POLOXAMER 407-PVP K30 INCLUSION COMPLEXES

Journal of Global Trends in Pharmaceutical Sciences Vol.2, Issue 4, pp , Oct -Dec 2011

Venkateswara Rao et.al Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online)

FORMULATION AND EVALUATION OF DILTIAZEM HYDROCHLORIDE COLON TARGETED TABLETS

FACTORIAL STUDIES ON THE EFFECTS OF HYDROXY PROPYL β- CYCLODEXTRIN AND POLOXAMER 407 ON THE SOLUBILITY AND DISSOLUTION RATE OF BCS CLASS II DRUGS

Design and Evaluation of Metoprolol Tartrate Containing Buccal Tablets

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS

Preparation and Evaluation of Silymarin Controlled Release Tablets Prepared Using Natural Gums

ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF NIMESULIDE BY CYCLODEXTRINS, POLOXAMER AND PVP

Journal of Global Trends in Pharmaceutical Sciences. Journal home page:

Vol-3, Issue-4, Suppl-1, Nov 2012 ISSN: Patel et al PHARMA SCIENCE MONITOR

Formulation and evaluation of immediate release salbutamol sulphate

OPTIMIZATION OF CONTROLLED RELEASE GASTRORETENTIVE BUOYANT TABLET WITH XANTHAN GUM AND POLYOX WSR 1105

Journal of Chemical and Pharmaceutical Research

Sivakasi , Tamil Nadu, India. ABSTRACT KEYWORDS:

FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD

Swamy P V*, Kinagi M B, Biradar S S, Gada S N and Shilpa H

Chemate and Chowdary, IJPSR, 2012; Vol. 3(7): ISSN:

Design and In-vitro Evaluation of Silymarin Bilayer Tablets

FORMULATION AND EVALUATION OF ACECLOFENAC SODIUM BILAYER SUSTAINED RELEASE TABLETS

EFFECT OF PVP ON CYCLODEXTRIN COMPLEXATION OF EFAVIRENZ FOR ENHANCING ITS SOLUBILITY AND DISSOLUTION RATE

FORMULATION AND EVALUATION OF BILAYERED TABLET OF METFORMIN HYDROCHLORIDE AND PIOGLITAZONE HYDROCHLORIDE

Asian Journal of Pharmacy and Life Science ISSN Vol. 2 (2), July-Sept,2012

International Journal of Pharma and Bio Sciences DEVELOPMENT AND CHARACTERIZATION OF LOVASTATIN CONTROLLED RELEASE BUCCOADHESIVE DOSAGE FORM

Bioadhesive buccal gels impregnated with fluconazole: formulation, in vitro and ex vivo characterization

Formulation and Evaluation of Medicated Nail Patches for the Treatment of Onychomycosis

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Research Article

ENHANCEMENT OF SOLUBILITY OF BICALUTAMIDE DRUG USING SOLID DISPERSION TECHNIQUE

Available online through ISSN

EVALUATION OF EFFERVESCENT FLOATING TABLETS. 6.7 Mathematical model fitting of obtained drug release data

Optimization of valsartan tablet formulation by 2 3 factorial design

Preparation and Evaluation of Ethyl Cellulose Coated Microcapsules of Carbamazepine for Controlled Release

A FACTORIAL STUDY ON THE ENHANCEMENT OF DISSOLUTION RATE OF KETOPROFEN BY SOLID DISPERSION IN COMBINED CARRIERS

FORMULATION AND CHARACTERIZATION OF TELMISATAN SOLID DISPERSIONS

DEVELOPMENT AND IN VITRO EVALUATION OF SUSTAINED RELEASE FLOATING MATRIX TABLETS OF METFORMIN HYDROCHLORIDE

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

FORMULATION DEVELOPMENT AND IN-VITRO CHARACTERIZATION OF BILAYER TABLETS OF AMOXICILLIN AND FAMOTIDINE

Pharma Research Library. 2013, Vol. 1(1): 34-44

A FACTORIAL STUDY ON ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF IBUPROFEN BY β CYCLODEXTRIN AND SOLUTOL HS15

PREPARATION AND INVITRO EVALUATION OF RABEPRAZOLE SODIUM DELAYED RELEASE ENTERIC COATED TABLETS

Volume: I: Issue-3: Nov-Dec ISSN

Formulation and evaluation of sublingual tablets of lisinopril

Formulation and evaluation of sustained release atenolol

A STUDY ON SUITABILITY OF NIMESULIDE-BETACYCLODEXTRIN COMPLEX IN ORAL AND TOPICAL DOSAGE FORMS

Maisammaguda, Dulapally, Secundrabad.

International Journal of Chemistry and Pharmaceutical Sciences

FORMULATION AND EVALUATION OF ETORICOXIB TABLETS EMPLOYING CYCLODEXTRIN- POLOXAMER PVPK30 INCLUSION COMPLEXES

Development And Evaluation Of Gastroretentive Floating Tablet Of Rosuvastatin

Feasibility of using natural gums for development of sustained release matrix tablet of itopride

Formulation and In vitro Release Characterization of Metoprolol Succinate Extended Release Tablets

FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS

Formulation and Evaluation of Bilayer Tablets of Glimepiride and Metformin HCL

Research Article Formulation and In-Vitro Evaluation of Fast Disintegrating Rosiglitazone Sublingual Tablets

CHAPTER 8 HYDROGEL PLUG FORMULATION AND EVAUATION

PREPARATION AND EVALUATION OF STARCH - PEG 1500 CO-PROCESSED EXCIPIENT AS A NEW DIRECTLY COMPRESSIBLE VEHICLE IN TABLET FORMULATIONS

Raviteja Achanta et al. IRJP 2012, 3 (9) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

Development and evaluation of controlled release mucoadhesive tablets of Tramadol Hydrochloride

Fabrication and evaluation of Nimesulide Azadirachta indica fruit mucilage based sustained release matrix tablets

Scholars Research Library

Research Article Formulation and Evaluation of Dual Component Tablets of Metoprolol tartrate

Pelagia Research Library

ENHANCEMENT OF SOLUBILITY, DISSOLUTION RATE AND BIOAVAILABILITY OF RITONAVIR BY CYCLODEXTRINS AND SOLUTOL HS15 - A FACTORIAL STUDY

Effect of Polymer Concentration and Viscosity Grade on Atenolol Release from Gastric Floating Drug Delivery Systems

Design and Characterization of Gastroretentive Bilayer Tablet of Amoxicillin Trihydrate and Ranitidine Hydrochloride for H.

Formulation and Evaluation of Gastroretentive Dosage form of Ciprofloxacin Hydrochloride.

DESIGN OF BUCCAL DRUG DELIVERY SYSTEM FOR A POORLY SOLUBLE DRUG

Formulation and evaluation of sustained release matrix tablet of metoprolol succinate

JOURNAL OF SCIENTIFIC & INNOVATIVE RESEARCH

Preparation and In vitro Evaluation of Mucoadhesive Tablets of Montelukast Sodium

CHAPTER VI FACTORIAL STUDIES ON THE EFFECTS OF CYCLODEXTRINS AND SOLUTOL HS15 ON THE SOLUBILITY AND DISSOLUTION RATE OF EFAVIRENZ AND RITONAVIR

FORMULATION AND EVALUATION OF BILAYERED TABLET OF METFORMIN HYDROCHLORIDE AND GLIMEPIRIDE

Evaluation of Ethyl Cellulose as Microencapsulating Agent for Controlled Release of Glimepiride

MODULATION OF GASTROINTESTINAL TRANSIT TIME OF SALBUTAMOL SULPHATE BY FLOATING APPROCHES

Formulation and evaluation of mucoadhesive bilayer buccal tablets of amphotericin B hydrocarbon

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE

Formulation and Evaluation of Bilayer Tablet by Wet Granulation

Optimization of Valsartan SR Floating Tablet Formulation by 2 2 Factorial Design and Multiple Regression Technique

Asian Journal of Pharmacy and Life Science ISSN Vol.3 (2), April-June, 2013

Formulation and evaluation of fast dissolving tablet of aceclofenac

Design and Characterization of Carbopol-HPMC-Ethyl Cellulose based Buccal Compact containing Propranolol HCl *

FORMULATION AND EVALUATION OF GASTRORETENTIVE FLOATING TABLETS OF FAMOTIDINE

Research Article Design and Development of Buccal Mucoadhesive Tablets of Metoprolol Succinate by using Cashewnut Tree Gum

Journal of Chemical and Pharmaceutical Research, 2012, 4(6): Research Article. Studies on Carica Papaya Starch as a Pharmaceutical Excipient

Formulation Development and Evaluation of Bilayer Floating Tablet of Antidiabetic Drugs

International Journal of Research in Pharmacology & Pharmacotherapeutics

Formulation and Evaluation of Losartan Potassium Buccal Tablets

FORMULATION DEVELOPMENT AND EVALUATION OF COLON TARGETED DOSAGE FORM OF IBUPROFEN

Transcription:

61 e- ISSN 0976-1047 Print ISSN 2229-7499 International Journal of Biopharmaceutics Journal homepage: www.ijbonline.com IJB FORMULATION AND EVALUATION OF BUCCOADHESIVE BILAYERED TABLETS OF CARVEDILOL Ankarao A*, Ch. Babu Rao 1, N. Devanna 2 *Department of pharmaceutics, Hindu College of Pharmacy, Guntur, Andhra Pradesh, India. 1 Department of chemistry, Donbosco Pg College of Pharmacy, Guntur, Andhra Pradesh, India. 2 Department of chemistry J.N.T.U College of Engineering, Anantapur, Andhra Pradesh, India. ABSTRACT The purpose of this research work was to establish mucoadhesive buccal tablets of carvedilol in the forms of bilayered tablets. The tablets were prepared using Hydroxy propyl methyl cellulose (HPMC K4M) and sodium carboxymethylcellulose (SCMC) and Carbopol-934 (CP) as bioadhesive polymers to impart mucoadhesion and ethyl cellulose (EC) to act as an impermeable backing layer. Buccal tablets were evaluated by different parameters such as weight uniformity, content uniformity, thickness, hardness, surface ph, swelling index, ex vivo mucoadhesive strength, in vitro drug release, and in vitro drug permeation. The mechanism of drug release was found to be non-fickian diffusion (value of n between 0.5 and 1.0) for both the buccal tablets. The present study concludes that mucoadhesive buccal tablets of carvedilol can be a good way to bypass the extensive hepatic first-pass metabolism and to improve the bioavailability of carvedilol. Key words: Bilayered buccal tablet, Buccal delivery, Mucoadhesion, Carvedilol. INTRODUCTION Carvedilol, a widely used for chronic asthma. Although it is well absorbed in the gastrointestinal tract, its bioavailability is low (14.8%) as a result of extensive first-pass metabolism. Since the buccal route bypasses the hepatic first-pass effect, the dose of carvedilol can be reduced. The physicochemical properties of carvedilol (Vishnu M. Patel et al., 2007), its suitable half-life (3-6 hours) (Leon Lachman et al., 1970; Vamshi Vishnu Y et al., 2007) and its low molecular weight 294.81 make it a suitable candidate for administration by the buccal route (Amir H Shojaei et al., 1998; Mishra BM et al., 2006; IP, 1996). In the present study, the objective was to Corresponding Author Ankarao A E-mail: ankaraopharmacy83@yahoo.com prepare mucoadhesive buccal tablets of carvedilol to prolong the residence time of the buccal tablets, which ensure satisfactory drug release in a unidirectional fashion to the mucosa, and to avoid loss of drug resulting from wash out with saliva. The buccal tablets were evaluated by weight uniformity, thickness, hardness, surface ph, swelling index, ex vivo mucoadhesive strength, In vitro drug release, and In vitro buccal permeation studies (Bottenberg P et al., 1991; De Vries ME et al., 1991). MATERIALS AND METHODS carvedilol (99.96% purity), were gift samples from Dr. Reddy s Labs Ltd, Hyderabad, India. Hydroxy propyl methyl cellulose (HPMC K4M), Sodium carboxymethylcellulose (SCMC, 400 cps), Carbopol-934 (CP), ethyl cellulose and D-mannitol (S.D. Fine Chemicals, Mumbai, India) were obtained from commercial sources. All other reagents and chemicals used were of analytical reagent grade.

62 Preparation of Mucoadhesive Buccal Tablets (Vyas SP et al., 1998; Amir H Shojaei et al., 1998) Mucoadhesive buccal tablets containing carvedilol were prepared by direct compression method. The ingredients of the core layer (Table 1) were weighed accurately and mixed by trituration in a glass mortor & pestle. The mix was then compressed using 8mm die by a tablet press. In order to obtain constant tablet weight the manitol was added as filler excipient in the core layer. After compression of tablet the upper punch was removed carefully without disturbing the set up and mixed ingredients of the backing layer (Table 1) were added over the tablet and compressed again. Evaluation parameters Ex Vivo Mucoadhesive Strength (Alka Gupta et al., 1992) A modified balance method was used for determining the ex vivo mucoadhesive strength. Fresh sheep buccal mucosa was obtained from a local slaughterhouse and used within 2 hours of slaughter. The mucosal membrane was separated by removing underlying fat and loose tissues. The membrane was washed with distilled water and then with phosphate buffer 7.4 saliva solution at 37 C. The sheep buccal mucosa was cut into pieces and washed with phosphate buffer ph 6.8. A piece of buccal mucosa was tied to the glass vial, which was filled with phosphate buffer. The glass vial was tightly fitted into a glass beaker (filled with phosphate buffer ph 6.8, at 37 C ± 1 C) so that it just touched the mucosal surface. The buccal tablet was stuck to the lower side of a rubber stopper with cyanoacrylate adhesive. The two sides of the balance were made equal before the study, by keeping a 5-g weight on the right-hand pan. A weight of 5 g was removed from the right-hand pan, which lowered the pan along with the tablet over the mucosa. The balance was kept in this position for 5 minutes contact time. The water (equivalent to weight) was added slowly with an infusion set (100 drops/min) to the right-hand pan until the tablet detached from the mucosal surface. This detachment force gave the mucoadhesive strength of the buccal tablet in grams. Swelling Study (Vyas SP et al., 1998) The swelling study of tables was determined by gravimetry. The swelling rate of the bioadhesive tablets was evaluated by using 1% agar gel plate. The average weight of the tablet was calculated (w 1 ). The tablets were placed on gel surface in a petridish placed in an incubator at 37 1ºC. Tablets was removed at different time intervals (0.5, 1.0, 2.0, 3.0, 4.0, 5.0), wiped with filter paper and reweighed (w 2 ). The swelling index was calculated by the formula. Swelling index = (w 2 w 1 )/ w Surface ph Study (Vyas SP et al., 1998) The surface ph of the buccal tablets was determined in order to investigate the possibility of any side effects in vivo. As an acidic or alkaline ph may cause irritation to the buccal mucosa, it was determined to keep the surface ph as close to neutral as possible. The method adopted by Bottenberg et al was used to determine the surface ph of the tablet. A combined glass electrode was used for this purpose. The tablet was allowed to swell by keeping it in contact with 1 ml of distilled water (ph 6.5 ± 0.05) for 2 hours at room temperature. The ph was measured by bringing the electrode in contact with the surface of the tablet and allowing it to equilibrate for 1 minute. In vitro dissolution studies The in vitro dissolution was carried out by using Tablets Dissolution Tester (USP-XXIII). The tablet is placed such that core faced to the dissolution medium (500 ml of 0.5%soidum lauryl sulphate). Dissolution medium temperature was maintained at 37 C and stirring at 50 rpm. An aliquot of the sample was periodically with drawn at suitable time intervals and the volume was replaced with fresh dissolution medium. The samples were analyzed spectrophotometrically at 242nm. In Vitro Buccal Permation Studies In vitro buccal permeation of carvedilol from matrix tablets through the goat buccal membrane was studied. The membrane was mounted over a Franz diffusion cell of i.d. 2.1cm and the selected F2 and F5 formulations containing 6.25 mg of carvedilol was placed onthe membrane. The receiver compartment of the diffusion cell was filled with 12.0 ml of alcohol: propylene glycol: phosphatebuffer saline ph 7.4 mixture (40:15:45).The entire setup was placed over a magnetic stirrer and the temperature was maintainedat 37 C by placing the diffusion cell in a water bath. One ml samples were collectedatpredetermined time intervals from the receptor compartment and replaced withan equal volume of the above mixture. The amount of carvedilol in the diffusion samples was estimated by the UV method. RESULTS AND DISCUSSION In the present work efforts have been made to develop mucoadhesive buccal tablets of carvedilol using direct compression technique involving mucoadhesive polymers like Carbopol, various cellulose ethers having different degree of solubility and swell ability, such as Hydroxy propyl methyl cellulose and Sodium carboxy methyl cellulose. Ethyl cellulose was selected as a backing material because this hydrophobic polymer has very low water permeability thus providing an impermeable backing layer that prevents drug loss. Magnesium stearate was included as anti adherent. The FTIR spectral analysis showed that there was no

63 appearance or disappearance of any characteristic peak, which confirms the absence of chemical interaction between drug and polymers. The blend of ingredients was analyzed for physical characteristics. The angle of repose of formulation blends F 1 to F 6 were in the range of 32º59' ± 1.464 to 33º20' ± 1.103. The bulk density, tapped density, Corr s index were found in the range of 0.433 to 0.317 gm/cc, 0.52-0.47gm/cc, and 16.66 14.28 respectively. It reveals that all the formulation blends were having good flow characteristics and flow rates. All the formulations pass the test for weight variation as per the IP standard ± 7.5 % deviation. Percentage of drug content for all formulations F 1 to F 6 was in the range of 96.1 ± 1.31 to 98.3 ±1.00 %. Thickness of F 1 to F 6 formulations was found to be 0.128 to 3.35 ± 0.106 mm. Hardness of all formulations F 1 -F 6 was found to be 5.2 ± 0.447 to 5.6 ± 0.548 kg/sq.cm. The bioadhesion and drug release profile are dependant upon swelling behavior of the tablets. Swelling index was calculated with respect to time.the Swelling index was for all formulations F 1 to F 6 (After 4 hours ) was in the range 1.119 ± 0.0346 to 1.120 ± 0.0370. Buccal tablets of all the formulations Surface ph values in the range of 7.0 ± 0.10 to 7.4 ± 0.05 that indicates no risk of mucosal damage or irritation. The bioadhesives property tablets of carvedilol containing varying proportions of polymers was determined with an insight to develop the tablets with adequate bioadhesiveness. The highest adhesion force and higest strength of the mucoadhesive bond was observed with the formulation as followed by F 2 to F 5 containing carbopol 934 p and Hpmc k4m and carbopol 934 and Scmc respectively, Tablets of formulation F 1 o F 6 containing Hpmc k4 m and Scmc alone showed least adhesion force than tablet of all other formulation. The mucoadhesive strength of all the formulations F 1 to F 6 was found to be in the range of 9.2 ± 0.16 to 10.4 ± 0.54 gms. The in vitro drug release of all the formulations F 1 to F 6 was found to be in the range of 93.02 ± 0.10 to 92.915 ± 053.Among the formulation studied F2 and F5 were found to be the best (F2 - CP-934-10mg, HPMC K4M-20mg, and mannitol-84.75mg as core layer and EC-45mg and Mag.Ste-5mg as backing layer and F5-CP- 934-10mg, SCMC-20mg, and mannitol-84.75 mg as core layer and EC-45mg and Mag.Ste-5mg as backing layer). The formulation F2 showed 98.61 0.80 percentage of drug released at 12 th hr with good swelling index and bioadhesion strength. The formulation F5 showed 97.61 1.10 percentage of drug released at 12 th hr with good swelling index and bioadhesion strength. Both F2 and F5 formulations obeyed zero order kinetics with non-ficikan diffusion mechanism and showed these two formulations were taken as optimized formulations for in vitro buccal permeation studies. Both Formulation F2 and F5 showed 86.90 1.10 and 83.40 0.85 respectively permeation drug through the buccal mucosa over a period of time 12 th hrs. Hence it can be conclusively stated the both F2 and F5 formulations necessary buccoadhesive property and the desirable release characterstics. However the detailed In vivo studies of the above formulations will through more light on their viability for consideration in the clinical practice. All the formulations exhibited anomalous (non-ficikan transport) diffusion mechanism and follow zero order kinetic. Table 4 the values of n were estimated by linear regression of log (Mt/M ) versus log t, and these values were between 0.5 and 1.0, indicating that the release of carvedilol was found to be non-fickian diffusion. Table:1COMPOSITION OF FORMULATIONS OF MUCOADHESIVE BUCCAL TABLETS Core Layer (mg) Backing Layer (mg) Formula code Drug (mg) CP-934 HPMC K 4M SCMC MANNITOL EC Mg.Ster F1 6.25 10 20-84.75 45 5 F2 6.25 15 15-84.75 45 5 F3 6.25 10-20 84.75 45 5 F4 6.25 20-10 84.75 45 5 F5 6.25 15-15 84.75 45 5 F6 6.25 20 10-84.75 45 5 Table 2. Physicochemical Properties of Bilayered Buccal Tablets of carvedilol* Batch Code Thickness Hardness % Drug Muco- (mm) (kg/cm 2 Surface ph ) Content adhesive Strength (g) F1 3.34 ± 0.128 5.2 ± 0.447 96.1 ± 1.31 7.0 ± 0.10 9.8± 0.16 F2 3.36 ± 0.203 5.4 ± 0.548 99.4 ± 1.52 7.2 ± 0.23 16.0 ± 0.12 F3 3.40 ± 0.057 5.8 ± 0.447 98.5 ± 1.31 7.3 ± 0.10 14.0 ± 0.16 F4 3.39 ± 0.061 5.6 ± 0.548 97.1 ± 1.46 7.1 ± 0.11 12.0 ± 0.16 F5 3.50 ± 0.147 5.4 ± 0.548 97.8 ± 1.45 6.9 ± 0.10 15.0 ± 0.08 F6 3.35 ± 0.106 5.6 ± 0.548 98.3 ± 1.00 7.4 ± 0.05 10.4 ± 0.54 *Each value represents the mean ± SD of 3 determinations

Cumulative % drug release Ankarao A. et al. / International Journal of Biopharmaceutics. 2013; 4(1): 61-65. 64 Table 3. In vitro dissolution studies for release kinetics Formula Code Drug release Kinetics Zero order First order Higuchi Peppa's K 0 r K 1 r r n r F 1 9.3036 0.99079 0.4429 0.732653 0.9804 0.66007 0.99994 F 2 8.17987 0.99571 0.369 0.856278 0.98607 0.76813 0.99652 F 3 9.44584 0.99561 0.1635 0.747604 0.98609 0.8558 0.9998 F 4 9.67705 0.99746 0.21105 0.855399 0.98477 0.85626 0.99693 F 5 10.323 0.99688 0.38107 0.891977 0.97015 0.82223 0.9971 F 6 8.6549 0.99617 0.31972 0.817707 0.96283 0.84842 0.99894 K 0 - Zero order rate constant r Coefficient of Correlation K 1 - First order rate constant n- diffusional exponent Table 4. Invitro buccal permeation studies for release kinetics Formula Code Drug release Kinetics Zero order First order Higuchi Peppa's K 0 r K 1 r r n r F 2 9.2456 0.99079 0.4245 0.792653 0.9804 0.82007 0.99994 F 5 8.7864 0.99571 0.4576 0.856278 0.9807 0.76813 0.99852 Figure 1. COMPRATIVE INVITRO DRUG RELEASE PROFILE FOR F1-F6 FORMULATIONS 100 90 80 70 60 50 40 30 20 10 0 0 2 4 6 8 10 12 Time in hrs F1 F2 F3 F4 F5 F6

65 CONCLUSION The mucoadhesive buccal tablets of carvedilol may be a good way to bypass the extensive hepatic first- pass metabolism and to improve the bioavailability of carvedilol through buccalmucosa. REFERENCES Alka Gupta, Sanjay Garg, Roop K Khar. Measurement of Bioadhesive strength of Mucoadhesive Buccal Tablets: Design of an In-vitro Assembly. Ind. Drugs, 1992; 4(30): 152-155. Amir H Shojaei. Buccal Mucosa as a rate for systemic drug delivery; A review. J. Pharm pharmceut sci. 1998; 1: 15-30. Bottenberg P, Cleymaet R, Muynek CD, Remon JP, Coomans D, Slop D. Development and testing of bioadhesive, fluoride-containing slow-release tablets for oral use. J Pharm Pharmacol. 1991; 43: 457-464. De Vries ME, Bodde HE, Verhoef JC, Junginger HE. Developments in buccal drug delivery. Crit Rev Ther Drug Carrier Syst. 1991; 8: 271-303. Indian Pharmacopoeia, Vol.II. edition 7, 1996, 734-736. Leon Lachman, Herberta lie berman, Joseph L Kanig. The theory and Practice and industrial pharmacy, Third edition, 1970, 293-345. Mishra B, CPS Narayan, C Sankar. Formulation and evaluation of verapamil hydrochloride buccal tablets. The Indian pharmacist. 2006; 117-120. Vamshi Vishnu Y, et al. Preperation and evaluation of mucoadhesive Buccal patch of carvedilol. Current Drug Delivery. 2007; 4(1): 27-39. Vishnu M Patel, Bhupendra G Prajapati, Madhabhai M Patel. Effect of Hydrophilic Polymers on Buccoadhesive Eudragit Patches of Propranolol Hydrochloride Using Factorial Design. AAPSPharmSciTech. 2007; 8(2): Article45. Vyas SP, Roop K Khar. Controlled Drug Delivery, 1998, 293-301.